1RW8

Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor

• PDB DOI:  https://doi.org/10.2210/pdb1RW8/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2003-12-16 Released: 2005-02-01 
• Deposition Author(s): Zhang, F., Sawyer, J.S.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.40 Å
• R-Value Free: 0.291 
• R-Value Work: 0.260 

Literature

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer, J.S., Beight, D.W., Britt, K.S., Anderson, B.D., Campbell, R.M., Goodson Jr., T., Herron, D.K., Li, H.Y., McMillen, W.T., Mort, N., Parsons, S., Smith, E.C., Wagner, J.R., Yan, L., Zhang, F., Yingling, J.M.

(2004) Bioorg Med Chem Lett 14: 3581-3584

• PubMed: 15177479 
• DOI: https://doi.org/10.1016/j.bmcl.2004.04.007
• Primary Citation of Related Structures:  
  1PY5, 1RW8


• PubMed Abstract: 
  

We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

---

Organizational Affiliation: 

Discovery Chemistry Research and Technology, The Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. [e-mail]

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 34.74 kDa 
• Atom Count: 2,545 
• Modelled Residue Count: 301 
• Deposited Residue Count: 301 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
TGF-beta receptor type I	A	301	Homo sapiens	Mutation(s): 0  Gene Names: Tru, TGFBR1, ALK5, SKR4 EC: 2.7.1.37 (PDB Primary Data), 2.7.11.30 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for P36897 (Homo sapiens) Explore P36897  Go to UniProtKB:  P36897
PHAROS:  P36897

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
580	B [auth A]	3-(4-FLUOROPHENYL)-2-(6-METHYLPYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE C18 H16 F N3 NBDZLUOYAAVYHF-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
580	Binding MOAD:  1RW8	IC50: 175 (nM) from 1 assay(s)
	PDBBind:  1RW8	IC50: 175 (nM) from 1 assay(s)
	BindingDB:  1RW8	IC50: 1320 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.40 Å
• R-Value Free: 0.291 
• R-Value Work: 0.260 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 41.961	α = 90
b = 84.961	β = 90
c = 84.085	γ = 90

Software Package:

Software Name	Purpose
HKL-2000	data collection
SCALEPACK	data scaling
AMoRE	phasing
CNS	refinement
HKL-2000	data reduction

Structure Validation

Entry History 

Deposition Data

• Released Date: 2005-02-01 
Deposition Author(s): Zhang, F., Sawyer, J.S.

Revision History  

• Version 1.0: 2005-02-01
  Type: Initial release
  
• Version 1.1: 2008-04-29
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance
• Version 1.3: 2023-08-23
  Changes: Data collection, Database references, Derived calculations, Refinement description